T3 Pharmaceuticals AG
Developing the next generation bacterial cancer therapy
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
23.11.2023
T3 Pharma acquired by Boehringer Ingelheim for CHF 450 Million to strengthen immuno-oncology portfolio (venturelab.swiss)
22.11.2023
Boehringer Ingelheim acquires T3 Pharma for up to CHF450 million (startupticker.ch)
28.04.2023
Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million (startupticker.ch)
02.09.2021
Fünf Unternehmerinnen und Unternehmer am SEF 2021 ausgezeichnet (startupticker.ch)
01.09.2021
On a growth path: Switzerland’s most promising scale-ups in 2021 (TOP 100)
No Jobs
Videos
T3 Pharma testimonial film from the Lichtsteiner Foundation
Presentation @Falling Walls Venture 2018
Venture 2016: Company presentation
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
TOP 100 Scale-ups
Being among the TOP 100 Startups in Switzerland has become a seal of approval for founders, and the TOP 100 Swiss Startup Ranking provides them with the recognition they deserve. As startups cannot appear in the startup ranking for more than five years after incorporation, the TOP 100 Swiss Scale-up Ranking has been introduced. A growth jury is asked to select the TOP 100 Swiss Scale-ups. These companies, aged five up to 10 years, show the greatest potential for further growth and represent the future Swiss unicorns
T3 Pharmaceuticals AG
Developing the next generation bacterial cancer therapy
Website:
www.t3pharma.com
Boehringer
Headquarter:
Allschwil
Foundation Date:
May 2015
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
Support received
